Abstract
Memantine, an aminodamantane, has recently been approved to treat moderate-to-severe Alzheimers disease in the US after over 20 years on the market in Europe for treatment of Parkinsons disease. The unique properties of Memantine allow for its selective inhibition of abnormally active NMDA receptor channels while preserving normal glutamate activity and healthy neuronal function. Recently, it has been shown that compounds such as nitroglycerin, used for years for ischemic coronary disease, can also regulate the NMDA receptor channel. Novel compounds have been synthesized in an attempt to combine these activities, in an attempt to synergistically improve upon the activities of both nitrates and aminoadamantanes. We have subjected these compounds to several laboratory tests to compare their ability to affect the function of the NMDA receptor and to dilate blood vessels. These tests provide an initial indication of which of the compounds may have enhanced activity relative to memantine. The results also provide guidance for the synthesis of additional compounds that are likely to have the properties that are being sought.
Keywords: NMDA receptor, S-nitrosothiol, Electrophysiology, memantine-binding domain, open-channel block
Current Alzheimer Research
Title: The Pharmacology of Aminoadamantane Nitrates
Volume: 3 Issue: 3
Author(s): Yuqiang Wang, Jerry Eu, Mark Washburn, Tong Gong, H.-S. Vincent Chen, W. Larrick James, Stuart A. Lipton, Jonathan S. Stamler, Gregory T. Went and Seth Porter
Affiliation:
Keywords: NMDA receptor, S-nitrosothiol, Electrophysiology, memantine-binding domain, open-channel block
Abstract: Memantine, an aminodamantane, has recently been approved to treat moderate-to-severe Alzheimers disease in the US after over 20 years on the market in Europe for treatment of Parkinsons disease. The unique properties of Memantine allow for its selective inhibition of abnormally active NMDA receptor channels while preserving normal glutamate activity and healthy neuronal function. Recently, it has been shown that compounds such as nitroglycerin, used for years for ischemic coronary disease, can also regulate the NMDA receptor channel. Novel compounds have been synthesized in an attempt to combine these activities, in an attempt to synergistically improve upon the activities of both nitrates and aminoadamantanes. We have subjected these compounds to several laboratory tests to compare their ability to affect the function of the NMDA receptor and to dilate blood vessels. These tests provide an initial indication of which of the compounds may have enhanced activity relative to memantine. The results also provide guidance for the synthesis of additional compounds that are likely to have the properties that are being sought.
Export Options
About this article
Cite this article as:
Wang Yuqiang, Eu Jerry, Washburn Mark, Gong Tong, Vincent Chen H.-S., Larrick James W., Lipton A. Stuart, Stamler S. Jonathan, Went T. Gregory and Porter Seth, The Pharmacology of Aminoadamantane Nitrates, Current Alzheimer Research 2006; 3 (3) . https://dx.doi.org/10.2174/156720506777632808
DOI https://dx.doi.org/10.2174/156720506777632808 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research White Matter Damage Along the Uncinate Fasciculus Contributes to Cognitive Decline in AD and DLB
Current Alzheimer Research The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Current Alzheimer Research Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Neurotoxicity of β-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Current Pharmaceutical Design Modulating the Amyloidogenesis of α-Synuclein
Current Neuropharmacology Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member:
Current Drug Safety Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Genes and Hypertension
Current Pharmaceutical Design A Synthesis of Functional Neuroimaging in the Frontal Variant of Frontotemporal Dementia
Current Medical Imaging Molecular Insights into Mechanisms of the Cell Death Program:Role in the Progression of Neurodegenerative Disorders
Current Alzheimer Research DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Editorial (Hot Topic: Organic Solute Transporters and Diseases: Potential Therapeutic Targets)
Current Molecular Pharmacology Mechanisms of Tau Self-Aggregation and Neurotoxicity
Current Alzheimer Research